116 related articles for article (PubMed ID: 15894403)
1. Prognostic factors in mesothelioma.
Steele JP; Klabatsa A; Fennell DA; Palläska A; Sheaff MT; Evans MT; Shamash J; Rudd RM
Lung Cancer; 2005 Jul; 49 Suppl 1():S49-52. PubMed ID: 15894403
[TBL] [Abstract][Full Text] [Related]
2. Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma.
Bottomley A; Coens C; Efficace F; Gaafar R; Manegold C; Burgers S; Vincent M; Legrand C; van Meerbeeck JP;
J Clin Oncol; 2007 Dec; 25(36):5770-6. PubMed ID: 18089874
[TBL] [Abstract][Full Text] [Related]
3. Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients.
Borasio P; Berruti A; Billé A; Lausi P; Levra MG; Giardino R; Ardissone F
Eur J Cardiothorac Surg; 2008 Feb; 33(2):307-13. PubMed ID: 18164622
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors for 100 patients with malignant pleural mesothelioma.
Gonlugur U; Gonlugur TE
Arch Environ Occup Health; 2010; 65(2):65-9. PubMed ID: 20439224
[TBL] [Abstract][Full Text] [Related]
5. A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma.
Berghmans T; Lafitte JJ; Paesmans M; Stach B; Berchier MC; Wackenier P; Lecomte J; Collon T; Mommen P; Sculier JP;
Lung Cancer; 2005 Oct; 50(1):75-82. PubMed ID: 16005104
[TBL] [Abstract][Full Text] [Related]
6. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
[TBL] [Abstract][Full Text] [Related]
7. Advances in the systemic therapy of malignant pleural mesothelioma.
Fennell DA; Gaudino G; O'Byrne KJ; Mutti L; van Meerbeeck J
Nat Clin Pract Oncol; 2008 Mar; 5(3):136-47. PubMed ID: 18227828
[TBL] [Abstract][Full Text] [Related]
8. Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board.
Kao SC; Vardy J; Chatfield M; Corte P; Pavlakis N; Clarke C; van Zandwijk N; Clarke S
Clin Lung Cancer; 2013 Jan; 14(1):70-7. PubMed ID: 22658812
[TBL] [Abstract][Full Text] [Related]
9. [Therapeutic options in malignant pleural mesothelioma].
Serke M; Loddenkemper R
Pneumologie; 2005 May; 59(5):337-48. PubMed ID: 15902599
[TBL] [Abstract][Full Text] [Related]
10. The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer staging system.
Flores RM; Routledge T; Seshan VE; Dycoco J; Zakowski M; Hirth Y; Rusch VW
J Thorac Cardiovasc Surg; 2008 Sep; 136(3):605-10. PubMed ID: 18805259
[TBL] [Abstract][Full Text] [Related]
11. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.
Fennell DA; Parmar A; Shamash J; Evans MT; Sheaff MT; Sylvester R; Dhaliwal K; Gower N; Steele J; Rudd R
J Clin Oncol; 2005 Jan; 23(1):184-9. PubMed ID: 15625372
[TBL] [Abstract][Full Text] [Related]
12. Staging and response to therapy of malignant pleural mesothelioma.
Heelan R
Lung Cancer; 2004 Aug; 45 Suppl 1():S59-61. PubMed ID: 15261435
[TBL] [Abstract][Full Text] [Related]
13. [Chemotherapy of malignant pleural mesothelioma: have we made any progress?].
Reck M; Heigener DF; Gatzemeier U
Zentralbl Chir; 2008 Jun; 133(3):238-42. PubMed ID: 18563688
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma.
Lucchi M; Chella A; Melfi F; Dini P; Ambrogi M; Fino L; Fontanini G; Mussi A
Eur J Cardiothorac Surg; 2007 Mar; 31(3):529-33; discussion 533-4. PubMed ID: 17188885
[TBL] [Abstract][Full Text] [Related]
15. Radical surgery for malignant pleural mesothelioma: results and prognosis.
Okada M; Mimura T; Ohbayashi C; Sakuma T; Soejima T; Tsubota N
Interact Cardiovasc Thorac Surg; 2008 Feb; 7(1):102-6. PubMed ID: 18048410
[TBL] [Abstract][Full Text] [Related]
16. Surgical staging and work-up of patients with diffuse malignant pleural mesothelioma.
Sugarbaker DJ; Norberto JJ; Swanson SJ
Semin Thorac Cardiovasc Surg; 1997 Oct; 9(4):356-60. PubMed ID: 9352952
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in malignant mesothelioma.
Burgers JA; Damhuis RA
Lung Cancer; 2004 Aug; 45 Suppl 1():S49-54. PubMed ID: 15261434
[TBL] [Abstract][Full Text] [Related]
18. Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy.
Nakas A; Trousse DS; Martin-Ucar AE; Waller DA
Eur J Cardiothorac Surg; 2008 Oct; 34(4):886-91. PubMed ID: 18656373
[TBL] [Abstract][Full Text] [Related]
19. Optimising survival in malignant mesothelioma.
Baas P
Lung Cancer; 2007 Aug; 57 Suppl 2():S24-9. PubMed ID: 17686442
[TBL] [Abstract][Full Text] [Related]
20. Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma.
Neragi-Miandoab S; Richards WG; Sugarbaker DJ
Int J Surg; 2008 Aug; 6(4):293-7. PubMed ID: 18585112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
